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Abstract 
 
In-hospital blood glucose regulation 
Michael Anthony LaDelfa 
 
This paper is a narrative review of the literature regarding in-hospital glucose 
regulation. Due to the increasing prevalence of diabetes in modern day medicine, 
proper management has never been more important. Acutely ill patients are at 
increased risk for developing hyperglycemia regardless of whether or not they have 
a pre-admission diagnosis of diabetes. The practice of maintaining tight glycemic 
control has been debated in the literature as it can be associated with an iatrogenic 
risk of hypoglycemia. However, there is a body of evidence that good glycemic 
control is associated with better outcomes. Currently, there is a consensus that blood 
glucose in hospitalized patients should be maintained below 10 mmol/L - an aim 
which might be individualized according to specific patient's variables and concurrent 
treatment plans. Insulin is recognized by most institutions as the treatment of choice 
in critically and non-critically ill patients in the hospital setting and is associated with 
better health outcomes compared to other modalities which are currently not 
recommended. However, in non-critically ill patients and those admitted for minor 
surgery their former treatment might be continued if blood glucose control is good. 
Stress hyperglycemia is fairly common in acutely ill patients and is associated with 
later development of new-onset diabetes thus reinforcing the value of effective 
communication and proper follow up in such patients. 
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Sažetak 
 
Regulacija glikemije u hospitaliziranih bolesnika 
Michael Anthony La Delfa 
 
Ovaj rad je narativni pregled literature o regulaciji glikemije u hospitaliziranih 
bolesnika. Zbog povećanja broja oboljelih od šećerne bolesti pravilno liječenje je od 
izuzetne važnosti za modernu medicinu. Oboljeli od akutnih bolesti isu imaju riziku 
natanka hiperglikemije bez obzira imaju li šećernu bolest od ranije ili ne. Striktna 
glukoregulacija u hospitaliziranih bolesnika je zadnjih godina dovedena u pitanje 
zbog velikog rizika jatrogene hipoglikemije i posljedično lošijih ishoda. S druge 
strane, jasni su dokazi da je dobra kontrola glikemije povezana s boljim ishodima 
liječenja. Aktualno je usuglašeno mišljenje da glikemiju u hospitaliziranih bolesnika 
treba držati nižom d 10 mmol/L. Taj cilj može biti individualiziran ovisno o 
karakteristikama bolesnika i pratećem liječenju. Inzulin se u većini institucija smatra 
terapijom izbora za kritične i nekritične hospitalizirane bolesnike i povezan je s boljim 
ishodima u usporedbi s drugim modalitetima koji se stoga ne preporučuju. Međutim, 
ako je glukoregulacija dobra u nekritičnih stabilnih bolesnika ili onih koji su primljeni 
radi manjih kirurških zahvata ranije se liječenje može nastaviti. Stres hiperglikemija 
je razmjerno česta u akutno oboljelih. Povezana je s rizikom kasnijeg razvoja 
šećerne bolesti. Stoga je važna edukacija tih bolesnika i kasnije adekvatno praćenje. 
 
Ključne riječi: Glukoza, Regulacija glikemije, Hospitalizacija, Stres hiperglikemija, 
Inzulin 
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Introduction 
 
Glucose irregularities are a commonly encountered problem in hospitalized patients 
and continue to be a costly yet seemingly preventable cause of prolonged hospital 
care in modern day medicine. Inpatient regulation of glucose levels in hospitalized 
patients not only applies to those with a pre-admission diagnosis of diabetes, but 
also patients without comorbidities who may be hospitalized in the general medicine 
ward, surgical ward or palliative care ward. Glucose regulation is a complicated 
matter that requires a good understanding of the underlying pathophysiology in 
different age groups and amongst different comorbidities, the variety of available 
treatments options and how these treatments must be modified under certain 
conditions with variables constantly changing in the hospital setting. Vigilant 
glycemic control is undoubtedly required in patients with a pre-admission diagnosis 
of diabetes, especially if the course of their disease has been poorly controlled as 
this can lead to high complication rates and longer length of hospitalization. 
Managing hyperglycemia in the hospital is particularly challenging due to the fact that 
patients experience many changes in medication regimens and nutritional intake with 
resultant fluctuations of glucose levels during the course of their care. The principle 
proportion of patients requiring proper attention to glycemic control are those who 
are admitted with pre-existing diabetes during their in-hospital treatment. Due to the 
expected increase in the incidence of diabetes on top of an already substantial 
number of affected patients, glucose management in the hospital has never been 
more important and efforts made to properly treat the risk of hyperglycemia and 
avoid its complications are of significant interest. Hospital complications and 
mortality can be significantly reduced with improvement in glycemic control (1). 
 
The World Health Organization (WHO) estimated that 422 million adults were living 
with diabetes in 2014, a number which is expected to rise reflecting the global 
increase of overweight and obese individuals (2). Individuals who have diabetes are 
more likely to be hospitalized than those without diabetes (3). This number increases 
in the elderly with a three times higher rate for those aged 65 years and older 
compared to those younger than 45 years as determined by the National Hospital 
Discharge Survey (NHDS) (4). The importance of proper glucose control cannot be 
overstated as there is a strong association between inpatient hyperglycemia and 
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overall adverse outcomes such as mortality, morbidity, infections, and length of 
hospital stay (5,6). Observational studies indicated a prevalence rate of in-hospital 
hyperglycemia around 31.7% for non-critical care patients and 46% for ICU patients 
(6,7). These numbers not only include diabetics but also patients without a pre-
admission diagnosis of diabetes and those who developed stress hyperglycemia in 
the hospital. Roughly 60% of patients who developed stress hyperglycemia in the 
hospital were found to have confirmed diabetes at one year post-hospitalization, 
despite the fact that their glucose values returned to normal before discharge (8). An 
important differentiator in determining patients with undiagnosed diabetes from those 
who developed stress hyperglycemia in the hospital is the measurement of an 
HbA1c value (9,10). According to The Endocrine Society, an elevated blood glucose 
HbA1c of greater than 6.5% can identify patients as having diabetes prior to 
admission (5). The American Diabetes Association (ADA) defines hyperglycemia as 
a blood glucose level in hospitalized patients >140mg/dL (7.8mmol/L) and 
hypoglycemia as glucose values <54mg/dL (3.0mmol/L) (11). Severe hypoglycemia 
is that characterized by substantial cognitive impairment irrespective of blood 
glucose values (11). Of clinical value however is a blood glucose of <70mg/dL which 
can be considered as a cautionary value of which titrations of insulin regimens may 
be based on (12). 
 
Mechanisms and Consequences of Stress Hyperglycemia 
 
Hyperglycemia is not only limited to patients with diabetes but also occurs during 
acute illness in patients who previously had normal glucose levels, in which case it is 
termed “stress hyperglycemia” (13,14). It is important to understand the 
pathophysiology and consequences of stress hyperglycemia as it is a commonly 
encountered reason for increased glucose levels in diabetic and non-diabetic 
hospitalized patients and a preventable source of adverse patient outcomes. 
Essentially the issue lies within an imbalance of hepatic glucose production and 
impaired peripheral glucose utilization, leaning towards an increase in production 
and decrease in utilization with subsequent increased blood glucose values. An 
interaction of glucoregulatory hormones, mainly insulin and the counter-regulatory 
hormones cortisol, glucagon, growth hormone and catecholamines, are responsible 
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for maintenance of blood glucose values. During acute stress, the counter-regulatory 
hormones predominate and alter carbohydrate metabolism by decreasing inducing 
insulin resistance, increasing hepatic glucose production and diminishing peripheral 
utilization of glucose (15). Furthermore, epinephrine which is released in the acute 
stress response stimulates glucagon secretion and inhibits pancreatic insulin 
release, all further contributing to increase blood glucose levels (16).  
 
The clinical sequelae of prolonged levels of hyperglycemia are well documented in 
the literature, however hospitalized patients can be subjected to further detrimental 
effects due to their comorbidities. An estimated 33% increase in mortality has been 
associated with each 1mmol/L (18mg/dL) rise in FPG (17). Studies following 
coronary artery bypass surgery patients irrespective of their pre-admission diabetes 
status had higher mortality rates, increased wound infections and longer hospital 
stays if their hospital blood glucose levels were elevated >200mg/dL compared to 
those with lower levels (18–20). A retrospective cohort study by Falciglia et al. found 
inconsistent findings when comparing hyperglycemia in hospitalized ICU patients 
and whether each patient is equally susceptible to the consequences of 
hyperglycemia and whether they will benefit from subsequent treatments (21). The 
researchers did find marked differences, specifically an increase in mortality 
amongst patients admitted for similar organ diseases if glucose levels were elevated 
in these patients (21). Every 2.2 mmol/L increase in glucose levels was associated 
with a 30% increase in post-operative infection rate in one study (22).  
 
Measuring Glucose Values  
  
Adequate control of blood glucose levels requires accurate and effective monitoring 
by the health care team. Patients with pre-existing diabetes and those who 
developed hyperglycemia in the hospital require close continuous monitoring. 
Because there are many variables that can alter the schedule for monitoring blood 
glucose in different patients, care must be taken in order to determine the special 
arrangements and set up a proper schedule in these patients. These variables 
include the patient’s nutritional intake, their individual medical treatment, and the 
schedule of their insulin administration (15). Proper alignment of these variables with 
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an appropriate monitoring and treatment schedule will ensure the most satisfactory 
control over blood glucose levels. For example, patients who are NPO receiving 
continuous intravenous insulin infusions in the ICU should have blood glucose levels 
measured every hour until stable levels are reached, in which a 2 hour schedule may 
be implemented (1). Patients receiving SC regular insulin every 6 hours or long 
acting basal insulin alone should have blood glucose measurements done every 6 
hours (15). For patients eating three meals per day using a basal long acting insulin 
plus rapid acting insulin with meals, blood glucose levels should be monitored 4 
times per day before meals and at bedtime regardless of the size of the meals and 
whether the patient is on high dose corticosteroids (15). Higher frequency of blood 
glucose monitoring not only allows treatment of elevated glucose levels but also 
prevents occurrences of hypoglycemia which can occur with over diligent use of 
insulin treatment (23). In patients without a history of diabetes, glucose values 
<7.8mmol/L without insulin therapy are a sufficient indication to end blood glucose 
testing (1). 
 
 
Figure 1. Blood Glucose Monitoring Algorithm (24). 
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Methods for obtaining blood glucose levels are fairly uniform throughout the 
literature. The most accurate method would be obtaining an arterial glucose level by 
using blood gas analyzers (25). This method is appropriate for use in critical care 
patients in the ICU as other accurate methods such as venous blood sampling are 
too time consuming (26). Handheld meters for POC testing are standard in hospital 
care for determining glucose values however their accuracy has been questioned as 
up to 20% in one study showed an inaccurate reading compared to plasma glucose 
levels (27). Inaccuracies can be a result of suboptimal hemoglobin levels in anemic 
patients, decreased tissue perfusion, hypotension and interactions with other 
medications (15). The ADA recommends that conventional laboratory tests with 
greater accuracy should be used to confirm glucose levels in patients whose clinical 
status does not correlate with the measured POC result due the possible 
discrepancies between samples of capillary, venous and arterial samples of blood 
(12). Continuous glucose monitoring (GCM) is another method employed by some 
hospitals which provides frequent measurements, helping protect against the 
dangers of hypoglycemia with treatment, however the literature does not fully 
support its use as it does not significantly improve glucose control and has 
subsequently not been recommended by a recent review (12,28).  
 
Proper monitoring of glucose values is still not optimal, and serves as an area of 
glucose management that should be given appropriate research in order to develop 
an appropriate standard which can correctly and quickly identify patients at risk while 
keeping nursing hours and cost efficiency in mind. For example, nurses consume 
approximately 4.7 minutes of patient hours and up to 2 hours of nursing time per day 
on certain patients, with the longer times attributable to finding blood glucose 
monitors, troubleshooting the devices and taking extra precautions when drawing 
blood from patients in isolation (29). Some nurses also believe that hourly glucose 
measurements are simply too much and prefer to keep monitoring to a minimum to 
avoid obtrusiveness and direct their time to other matters (29). This dilemma has 
been noticed by many companies worldwide as efforts are underway to create a 
continuous glucose monitoring tool using fibre optics, infrared technology and 
transdermal methods that are unobtrusive, accurate and reliable after previous 
attempts to create such technologies have had limited success (30).  
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Glycemic Targets  
 
The literature is fairly consistent in recommendation values for optimal glycemic 
control however debates arise over how strict the recommended glucose range 
should be set and whether there is any discernable advantage of adopting tight 
glycemic control versus having a more conservative approach. Due to variations in 
hospitalized patients’ nutritional status and other factors contributing to their 
comorbidities, higher than normal glucose targets can be advised for these patients 
opposed to those who are in outpatient care (31). Therapy should be initiated in the 
majority of critically ill and non-critically ill patients who have consistent levels of 
hyperglycemia once they have crossed a threshold of >180 mg/dL (10.0 mmol/L) 
and maintained in a target glucose range of 140-180 mg/dL (7.8-10.0 mmol/L) (31). 
These glucose ranges are maneuverable however and are not a set standard for all 
hospitalized patients. Certain patients may be given more aggressive goals of < 140 
mg/dL (<7.8 mmol/L) though glucose levels must be monitored appropriately to 
prevent hypoglycemia (12). On the other hand, if patients are in a position where 
strict glucose monitoring is simply not possible or glucose control is perhaps second 
to other more significant issues in their medical care such as palliation or severe 
comorbidities, then a higher target glucose range may be explored (12). Because of 
these outliers, an individualized approach to target glucose values may be worth the 
extra effort as treatment can be tailored to each individual patient to decrease 
hyperglycemia risk and avoid hypoglycemia due to overaggressive therapy.  
 
Management of Hyperglycemia in Non-Critically Ill Inpatients 
 
There are many different strategies for approaching the hyperglycemic patient that 
should be taken into consideration however for simplicity and effectiveness the use 
of insulin has become the mainstay of hyperglycemia in the hospital setting. The 
traditional use of sliding scale insulin was once considered an essential treatment 
method of high blood glucose levels but has now been considered inappropriate for 
safe management in hospitalized patients. The risk of inadequately treated 
hyperglycemia and severe hypoglycemia in patients treated with the use of sliding 
scale insulin had become far too common and increased complication rates in the 
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hospital (3,32). In general medicine and surgery patients who are not in critical care, 
subcutaneous short-acting insulin before meals or every 4-6 hours if NPO has 
become the mainstay of treatment to adequately control hyperglycemia in diabetics 
and non-diabetics (12,15). When possible, specifically in patients who are being fed, 
an insulin regimen that simulates physiological secretion is preferred. The basal 
bolus (prandial) insulin regimen is effective because it follows the physiological 
response by covering the basal, nutritional and supplemental requirements of insulin 
production (33). Well controlled glucose levels, less hypoglycemia and elimination of 
frequent feeding to prevent hypoglycemia were all achieved by one study using this 
regimen (33). In patients receiving enteral nutrition therapy, a basal insulin dose with 
consequent postprandial insulin doses resulted in lower levels of hyperglycemia 
compared to sliding-scale regular insulin regimens and decreased the risk of adverse 
events (34). A study by Korytkowski et al. found increased baseline glucose levels, 
greater insulin requirements, increased adverse outcomes, and a greater incidence 
of hypoglycemia in patients treated with sliding-scale regular insulin versus a basal 
dose of insulin glargine with SSRI (34). In patients being treated solely with SSRI 
therapy, they had a three times greater chance of having blood glucose levels 
>300mg/dL compared to those given basal-bolus insulin (9). A prospective 
randomized multicenter trial found 14% of patients being treated with sliding-scale 
insulin therapy had a blood glucose > 240mg/dL despite administering higher insulin 
doses compared to patients treated with insulin glargine and glulisine, though no 
differences in length of hospital stay or incidence of hypoglycemia were noted (35). A 
sliding-scale regimen can be of use for initial therapy in non-diabetic patients with 
moderate hyperglycemia, however these patients should be transitioned to a 
scheduled insulin regimen once insulin requirement is determined (34). The issue 
with treating patients with SSRI therapy is that the underlying mechanism acts to 
correct hyperglycemia only when it occurs and has no beneficial effect of preventing 
or decreasing recurrences of hyperglycemia, something which a basal-bolus regimen 
can achieve.  
 
The use of a constant intravenous insulin infusion has the benefit of a very rapid 
achievement of glycemic control however it is not recommended in non-critical care 
patients in many hospitals, especially when feeding protocols are subject to change, 
requiring insulin dosage to be adjusted accordingly (36). If patients are being 
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weaned off of intravenous insulin during their hospital care, a proper transition 
protocol to subcutaneous insulin can lower costs and prevent morbidity and is thus 
recommended (37). Consideration about the patient’s age, comorbidities, renal 
function, and nutritional intake should all influence the clinician’s decision about the 
amount of total daily insulin required for patients. Most patients should be started 
with a starting total daily dose of insulin between 0.3 and 0.5 units/kg as higher 
doses greater than 0.6 to 0.8 units/kg/day have been associated with hypoglycemia 
(13,29,36,38). The seemingly increased safety profile of basal bolus (prandial) 
insulin regimen as well as its success rate of achieving and maintaining appropriate 
glucose levels in treated patients should lead to its uniform implementation in 
hospitalized non-critical care patients. 
 
Noninsulin antihyperglycemic treatments are currently not recommended in the 
treatment of hospitalized patients as evidence regarding safety and efficacy is 
lacking. Research is currently being conducted to determine if there is any benefit 
using oral hyperglycemic agents compared to the current insulin standard with some 
initial promising results (12). One study indicated that glycemic control using 
sitagliptin alone or in a combination with insulin showed improved blood glucose 
levels in all patient groups, with less dosing and injections of insulin required in the 
sitagliptin combination group versus the basal bolus group (39). When compared to 
using insulin treatment, oral agents undergo a different pathway for distribution in the 
body and different mechanisms of action with delayed onset of therapeutic goals, 
meaning its use would better be served for treatment of outpatient hyperglycemia 
rather than the inpatient setting that requires rapid correction. Many inpatients in the 
hospital have clear contraindications for the use of certain oral antihyperglycemic 
agents. Metformin is generally not prescribed for patients with renal insufficiency, 
hepatic and cardiovascular disease due to concerns over lactic acidosis though its 
use in the hospital is still common despite these concerns (39). Sulfonylureas act as 
long-acting insulin secretagogues and are very commonly used in patients with type 
2 diabetes however their side effect profile includes a high risk of hypoglycemia, 
limiting its use for inpatients (40). A nested case-control study showed 19% of 
hospitalized patients taking a sulfonylurea developed hypoglycemia, with the majority 
of cases occurring in patients older than 65 years, those with decreased GFR of 
30ml/minute/1.73m2 and those who were receiving concurrent intermediate or long-
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acting insulin while being treated with a sulfonylurea (41). Patients being treated with 
a sulfonylurea have the increased risk of prolonged hypoglycemia due to the 
pharmacodynamics of the agent, and require further monitoring and strict 
management with glucose preparations (41). Other oral antihyperglycemic agents 
such as thiazolinediones, Sodium glucose co-transporter 2 inhibitors, α-glucosidase 
inhibitors and incretin based therapies generally have side effect profiles and 
contraindications in hospitalized patients that substantially limit their use for inpatient 
treatment.  
 
Management of Hyperglycemia in Critically Ill Inpatients 
 
Insulin is indisputably the gold standard for treating critically ill patients in the hospital 
setting, as agreed upon by the majority of the literature. Intravenously administered 
insulin is preferred due to its rapid delivery which allows for quick correction of 
deteriorating glucose levels with greater predictability and effectiveness compared to 
subcutaneously administered insulin (1). However, infusing insulin intravenously is 
quite labour intensive and in a majority of health centres requires ICU admission for 
proper administration and monitoring (1). In the critical care setting, predetermined 
written or computer protocols factoring glycemic fluctuations and insulin dose may be 
used for adjustments of the infusion rate when considering infusing patients with 
insulin (31). Obvious fluctuations in the patients’ clinical status and glucose targets 
should be accounted for when adjusting insulin infusion rates. Traditionally a blood 
glucose target was achieved by using a drip which was mathematically calculated by 
the medical staff using an established algorithm (42). Unfortunately, errors in dosing 
can be common due to human errors which is why computer protocols have set the 
stage to replace simple predicting on the physicians part (15). Computer based 
algorithms proved to deliver tighter glycemic control with less risk of hypoglycemia 
when compared to the traditional paper protocol (42).  
 
Hypoglycemia in Hospitalized Patients 
 
Hypoglycemia can occur in hospitalized patients due to aberrations in feeding times, 
NPO orders, interactions with medications, problems with feeding mechanisms and 
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over judicious use of insulin or other antihyperglycemic agents. Hypoglycemia in 
patients being treated with intensive insulin therapy can occur frequently and has 
been shown to be a risk factor for death in hospitalized patients (18).  There is a 
divide in the literature between the benefits and risks of using tight glycemic control 
with regards to subsequent hypoglycemia. A study by Furnary et al. discovered that 
tight glucose control with continuous insulin infusion in diabetic patients being treated 
with coronary artery bypass grafting was significantly better at controlling glucose 
levels and decreased the mortality that beset these patients in the past (43). On the 
contrary, a magnitude of studies have demonstrated significantly elevated risks of 
hypoglycemia with tight glycemic control. The Glucontrol study found an 8.7% 
increased risk in patients being treated with tight glycemic control (4.4-6.1 mmol/L) 
compared to the conventional group (7.8-10 mmol/L), with sicker patients having a 
greater risk of hypoglycemia and death (44). The NICE-SUGAR study found that 
while there was not a significant difference in the amount of days spent in the ICU or 
hospital between intensive-control groups and conventional-control groups, 6.8% of 
patients in the former group developed severe hypoglycemia (<2.2 mmol/L) 
compared to only 0.5% of patients in the later (45). The researchers concluded that a 
blood glucose target of ≤180 mg/dL resulted in a lower mortality than a tight glycemic 
target between 81-108 mg/dL (45).  
 
The importance of preventing hypoglycemia is significant as its occurrence has been 
associated with many serious adverse outcomes in hospitalized patients. The 
ADVANCE study found severe hypoglycemia being a contributing factor in the 
development of major macrovascular and microvascular events, and all-cause 
mortality but also found hypoglycemia to be a marker of vulnerability to these events 
(46). The fact that a patient exhibits severe hypoglycemia during glucose-lowering 
intervention should prompt evaluation into their susceptibility for adverse outcomes 
and address the associated issues that may arise (46). Another study in acute 
myocardial infarction patients determined that iatrogenic hypoglycemia was not 
associated with a higher mortality risk compared to patients who developed 
spontaneous hypoglycemia, and that only spontaneous hypoglycemia was a risk 
factor for increased mortality (47). The evidence is debatable and more research 
should be conducted to determine the correlation between iatrogenic hypoglycemia 
and all cause morbidity and mortality, although the literature can agree that 
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hypoglycemia in hospitalized patient is at the very least marker for vulnerability to 
adverse events and should be avoided at all costs. The American Diabetes 
Association acknowledges that hypoglycemia may just be a marker of underlying 
disease and not a cause of mortality, however they do recommend that 
hypoglycemia be avoided until the link can be proven (12). 
 
 
Hyperglycemia in High Risk Patients 
 
Certain subsets of patients are deemed high risk due to their underlying 
comorbidities, concurrent medications and procedures in the hospital which can 
contribute to hyperglycemia. Corticosteroids, which are commonly used in the 
hospital as a single therapy or in combination therapies, can contribute to 
hyperglycemia more commonly by late morning when it is prescribed, but can have a 
prolonged effect throughout the course of the day if daily doses are required (15). It 
is essential to monitor capillary blood glucose values in patients on high dose 
corticosteroids, especially during the period 4 to 8 hours after oral administration and 
sooner after intravenous administration (15). A basal dose of intermediate or long-
acting insulin may be able to offset the increased glucose levels of early morning 
corticosteroid therapy, however care should be taken to avoid episodes of 
hypoglycemia when long acting insulin preparations are used in these cases (15). 
The COIITSS study hypothesized that patients being treated for septic shock in the 
ICU with corticosteroids may benefit with intensive insulin therapy versus a 
conservative therapy, even though general ICU patients may not (48). Prolonged 
bed rest for as little as seven days in hospitalized patients may also contribute to 
insulin resistance in skeletal muscle and decreased glucose uptake (49). Severe 
hyperglycemia (minimum 9.99 mmol/L) has been shown to increase the likelihood of 
developing graft versus host disease in nondiabetic patients after allogenic stem-cell 
transplantation, though the researchers’ results were found in non-obese patients 
only (50). One study analyzing cardiac surgery patients found that while glucose 
concentrations were lower at the end of surgery with intensive insulin treatment, 
there was no decrease in perioperative death and mortality between this group and 
the conventional treatment group, in fact showing more deaths and strokes in the 
intensively treated group (51). Intensive glycemic control in the range of 80-180 
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mg/dL (4.4-10 mmol/L) was not shown to benefit perioperative patients with diabetes 
undergoing surgical procedures and showed a higher incidence of hypoglycemia in 
these patients, advising against practicing tight glycemic control in surgical patients 
(52). A multicenter randomized trial found improved glycemic control in general 
surgery patients with a basal plus regimen with glargine once daily and corrective 
glulisine before meals compared to a standard basal-bolus regimen (52).  
 
Nutritional Therapy in Hospitalized Hyperglycemic Patients 
 
Nutritional therapy is an essential component in the treatment plan of hospitalized 
patients and requires special attention in patients with new onset hyperglycemia or 
diabetes since their nutritional requirements differ from those in the outpatient 
setting. Ultimately nutritional therapy can serve as a useful tool if managed properly 
or can become a hindrance in patient care by causing more problems that require 
further treatment. Like all hospitalized patients, it is important that a specialized meal 
plan be tailored to their individual needs to provide adequate nutritional intake while 
avoiding hyperglycemia or hypoglycemia. A nutritional professional should work very 
closely with health care providers when treating patients with diabetes or new onset 
hyperglycemia in the hospital (15). When considering providing medical nutrition 
therapy to patients with elevated glucose levels, the first step should be to determine 
whether the patient requires more in depth assessment by implementing a screening 
and referral process (53). While an individualized nutritional program should be 
implemented in all patients with diabetes or hyperglycemia, three discrete meals 
should be adequate to achieve their caloric needs (15). The ADA does not advise a 
specific meal plan or percentage of macronutrients, however the patient’s 
physiological parameters, treatment goals and current medications should all factor 
into a favourable nutritional plan (12). If possible, whole grains and vegetables 
should be the primary source of carbohydrates due to their low glycemic index (15). 
In patients who cannot tolerate oral feeds, the next best option is enteral nutrition 
and is preferred over parenteral nutrition in hospitalized patients (54). This is due to 
the lower cost, lower complication rate, less risk for atrophy of the gastric mucosa 
and lower risk of the complications associated with parenteral therapy such as 
infectious and thrombotic complications (55). Many hospitals prefer using a 
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consistent carbohydrate meal plan as intake carbohydrate intake can be matched 
with a prandial insulin dose to offset any increase in blood glucose levels that may 
occur by unregulated nutritional intake (56).  
 
Communication and Discharge of Hyperglycemic Patients 
	
The transition of a hospitalized diabetic or hyperglycemic patient to the outpatient 
setting can be difficult, thus requiring careful discharge orders and proper 
communication to prevent outpatient complications. Generally a patient with an 
HbA1C of less than 6.5% can be discharged with no antidiabetic treatment, and 
those with elevated HbA1C levels should be prescribed insulin, oral 
antihyperglycemic agents or combination therapies for the outpatient setting (1). 
Proper communication is imperative to ensure the patient administers their treatment 
correctly and at the appropriate times in order to prevent aberrations in their glucose 
levels. Due to the complexity of insulin treatment regimens, it is recommended that 
written orders be given to the patient as oral communication can lead to errors and 
complications in management (1). To prevent these types of errors, several 
organizations have implemented strategies that incorporate clear, formal discharge 
instructions about medications and follow up appointments, however evidence is still 
lacking regarding the ideal method of providing a safe transition to the outpatient 
setting (57). Part of the importance in proper outpatient management of these 
patients is that hyperglycemic patients may be at increased risk of future preventable 
morbidities. A systematic review found that patients who have been treated for stress 
hyperglycemia in the hospital are at increased risk for developing subsequent 
diabetes and should be followed up accordingly (58). Another study determined a 
prevalence of new-onset diabetes of 8% in stress hyperglycemia patients during 
follow up, and noted a positive correlation between the degree of in-hospital 
hyperglycemia and risk of subsequent diabetes development (59). Hospitalized in-
patients with severe hyperglycemia showed a striking 28% increased risk of 
developed new-onset diabetes after discharge (59). This perceived link necessitates 
further research into the development of new-onset diabetes in stress-hyperglycemia 
patients and reiterates the importance of proper discharge orders and follow up 
appointments in such patients as research on the pathophysiology of such events is 
still lacking. 
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Discussion 
 
The global burden of obesity and overweight individuals is contributing to an 
overwhelming increase in the prevalence of diabetes in the population. 
Unfortunately, these patients are susceptible to greater health risks which must be 
managed appropriately to prevent further morbidity and mortality. The hospital 
setting proves to complicate the treatment of these patients due to 
pathophysiological mechanisms under the stress state of acute or chronic illness, 
comorbidities altering treatment plans, newly prescribed medications and a different 
and sometimes unpredictable nutritional intake. Development of hyperglycemia not 
only applies to patients with a pre-admission diagnosis of diabetes but also develop 
sporadically as "stress" hyperglycemia in acutely ill patients. These patients 
seemingly are increased risk for the future development of new-onset diabetes. 
Hyperglycemia has many clinical complications that can increase morbidity, hospital 
stay and even mortality in some patients and should be avoided by proper 
monitoring of blood glucose levels and prompt treatment when required. Monitoring 
of glucose levels in the hospital is adequate however advancements should be made 
to develop a continuous, non-obtrusive means of obtaining measurements which can 
cut down on health care costs and decrease nursing time spent on constantly 
measuring these patients. Excessive or inappropriately timed treatment with insulin 
and antihyperglycemic agents may lead to dangerously low glucose levels so care 
must be taken when setting up a treatment plan for diabetic patients and patients 
with stress hyperglycemia. Nutritional intake and the route of administration can 
significantly change the treatment plans and must be factored in by the health care 
team, including a professional nutritionist. Glycemic targets can vary in individual 
patients depending on their clinical status and comorbid disease severity, therefore 
no gold standard glycemic target has been developed and relies somewhat on 
clinical experience and judgement. Insulin is recognized across the literature as the 
treatment of choice in treating hyperglycemic patients in the hospital setting as it has 
a rapid and predictable course of action. Antihyperglycemic agents are generally 
avoided in the hospital as evidence cannot recommend them in light of the fact that 
they are associated with harmful side effects with little benefit compared to insulin. 
Nutritional therapy is another important aspect of the treatment plan of 
hyperglycemic patients and should be approached with caution by a nutritional 
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professional and the health care team to factor in all patient and treatment variables. 
Parenteral nutrition should be avoided in patients who cannot tolerate oral feeding as 
enteral nutrition has been shown to be associated with less complications. Upon 
discharge of hospitalized diabetics or patients who developed hyperglycemia, proper 
communication is imperative to ensure these patients follow their treatment plans 
properly and understand the details and importance of their follow up appointments.  
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